Two Sigma Advisers’s Verve Therapeutics VERV Stock Holding History

Two Sigma Advisers’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-381,300	Closed	-$4.28M	–	2651
2025 Q2	$4.28M	Buy	381,300 +207,500	+119%	+$1.18M	0.01%	789
2025 Q1	$794K	Sell	173,800 -119,400	-41%	-$800K	﹤0.01%	1573
2024 Q4	$1.65M	Buy	293,200 +108,600	+59%	+$613K	﹤0.01%	1213
2024 Q3	$893K	Sell	184,600 -54,100	-23%	-$314K	﹤0.01%	1464
2024 Q2	$1.16M	Buy	238,700 +202,000	+550%	+$1.27M	﹤0.01%	1474
2024 Q1	$487K	Buy	+36,700	New	+$487K	﹤0.01%	1882

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Advisers's VERV Position: Q3 2025 in Review

Two Sigma Advisers sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 381,300 shares — an estimated $4.28M sold.

Two Sigma Advisers first reported a position in VERV in Q1 2024 and held it in 6 quarters. The position peaked at $4.28M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Two Sigma Advisers reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Two Sigma Advisers sold 381,300 Verve Therapeutics shares in Q3 2025, an estimated $4.28M.
Two Sigma Advisers first reported a position in Verve Therapeutics in Q1 2024 and held it in 6 quarters.
Two Sigma Advisers's Verve Therapeutics position peaked at $4.28M in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.